Search

Your search keyword '"Gattermann, N"' showing total 844 results

Search Constraints

Start Over You searched for: Author "Gattermann, N" Remove constraint Author: "Gattermann, N"
844 results on '"Gattermann, N"'

Search Results

1. The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

4. Aktuelle Entwicklungen in der interdisziplinären Krebstherapie

8. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

9. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS

10. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

11. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

12. Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo

14. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS

15. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

16. P090 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

17. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

20. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians

23. P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY

24. P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA

25. Pharmakologie und Pharmakotherapie

34. Results from the phase-Ib/II combination trial MPNSG-0212 : Ruxolitinib plus pomalidomide in myelofibrosis with anemia

35. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

38. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

45. Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

49. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

Catalog

Books, media, physical & digital resources